Please select the eligibility criteria that correspond to the clinical trial below.
Title: Vitamin D Supplementation and CD4 Count in HIV-Infected Children
Brief Summary: To find out if vitamin D supplementing can lead to an improvement in immunological status in HIV-infected children as part of routine clinical care


Options:
A: Inclusion Criteria:

* 4-8 years at the start of the intervention
* healthy
* of white, Danish/European origin
* children must be Danish-speaking
* parents must read and speak Danish
* not planning a winter vacation south of a latitude of 51°North (corresponding to Surrey, England)

Exclusion Criteria:

* diseases that may interfere with vitamin D or calcium metabolism
* intake of medication known to affect vitamin D or calcium metabolism
* use of vitamin D containing supplements ≥ 4 days/week the last 8 weeks before intervention start and use of any vitamin D containing supplements the last 4 weeks before intervention start
* concomitant participation in other studies involving dietary supplements or blood sampling
* serum calcium \> 2.7 mmol/L at baseline
B: Inclusion Criteria

* All the selected children of Severe uncomplicated acute malnutrition of concerned age group whose parents or guardians have give written consent for the study
* Mid Upper Arm Circumference (MUAC) less than 11.5 cm or Weight For Height (WFH) less then minus 3 standard deviation.

Exclusion Criteria

* Children above the concerned age group
* Refusal of parents for taking part in the study.
* Child having Severe Acute Malnutrition (SAM) with complications have loss of appetite, lower respiratory tract infection indicated by chest in drawing, severe vomiting.
* Temperature greater then 39°C or hypothermia less then 35°C, very pale, oedema, unconsciousness.
C: Inclusion Criteria:

* HIV-infected children as defined by ≥ 2 positive HIV DNA PCRs and/or HIV cultures of blood for children less than 18 months of age, or by positive screening and confirmatory serologic testing in those older than 18 months of age
* Stable HIV disease, defined by the absence of change in HIV clinical or immunologic category during the preceding 6 month period, prior to commencing the study
* Age 3 years through 18 years
* Voluntary informed consent

Exclusion Criteria:

* Any antiretroviral medication change in the 6 months prior to the study, or any anticipated antiretroviral medication change during the duration of the study
* Active participation in another treatment trial
* Serum calcium \< 2mmol/L at baseline
D: Inclusion Criteria:

* Clinical diagnosis of stage 2-5 Chronic Kidney Disease (estimated glomerular filtration rate \[GFR\] between 15 and \< 90 ml/min/1.73m2) based on the new bedside Schwartz formula estimation using serum creatinine and height \[height in cm x 0.413/serum creatinine\]
* 1-21 years of age
* Willingness and ability to provide informed consent and assent

Exclusion Criteria:

* Children less than 1 year of age (in whom risk of vitamin D toxicity may be increased) or greater than 21 years at time of study screening
* Children with a documented history of hypercalcemia or nephrolithiasis
* Children with GI tract discontinuity (ostomy)
* Current pregnancy or pregnancy within the last 12 months
* Children with known anemia-related disorders including sickle cell anemia, thalassemia
* Children with severe 25D deficiency (\< 5 ng/mL) likely to be associated with severe morbidity and requiring prompt high dose vitamin D supplementation, or with 25D levels \> 60 ng/mL which could be associated with increased risk of vitamin D toxicity

Answer: C